SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

8295	Companies
114810	Keywords
55260	Articles
62423	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 10/25/2024 at 07:30, 27 days 2 hours ago

Communiqué de presse : T3 2024 : Croissance des ventes de 15,7% soutenue par une séquence des ventes de vaccins plus favorable qu’anticipée; Sanofi relève ses perspectives de BNPA des activités 2024 suite à la forte performance
PRESS RELEASE

published on 10/25/2024 at 07:30, 27 days 2 hours ago

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
BRIEF

published on 10/24/2024 at 14:05, 27 days 19 hours ago

Publication de données positives de phase 3 pour Dupixent dans l'urticaire chronique spontanée

Dupixent Urticaire Chronique Spontanée Données De La Phase 3 Présentation De L'ACAAI Innovation En Matière De Traitement
BRIEF

published on 10/24/2024 at 14:05, 27 days 19 hours ago

Positive Phase 3 Data for Dupixent in Chronic Spontaneous Urticaria Released

Dupixent Chronic Spontaneous Urticaria Phase 3 Data ACAAI Presentation Treatment Innovation
PRESS RELEASE

published on 10/24/2024 at 14:00, 27 days 19 hours ago

Communiqué de presse : Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI
Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI. Les résultats du Dupixent montrent une réduction significative du prurit et de l'activité de l’urticaire

Traitement Dupixent Phase III Urticaire Chronique Spontanée ACAAI
PRESS RELEASE

published on 10/24/2024 at 14:00, 27 days 19 hours ago

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent phase 3 data in chronic spontaneous urticaria presented at ACAAI shows reduced itch and hive activity, potential new treatment for CSU patients

Dupixent Chronic Spontaneous Urticaria ACAAI Phase 3 Data Targeted Treatment
BRIEF

published on 10/21/2024 at 07:35, 1 month ago

Sanofi et CD&R unissent leurs forces pour faire croître Opella

Transaction Financière Sanofi CD&R Opella Santé Grand Public
BRIEF

published on 10/21/2024 at 07:35, 1 month ago

Sanofi and CD&R join forces to grow Opella

Financial Transaction Sanofi CD&R Opella Consumer Health
PRESS RELEASE

published on 10/21/2024 at 07:30, 1 month ago

Communiqué de presse : Sanofi et CD&R s’allient pour soutenir les ambitions d’Opella dans la santé grand public
Sanofi et CD&R s'allient pour soutenir Opella dans la santé grand public. Opella devient un leader indépendant avec le soutien de Sanofi. CD&R apporte son expérience pour accélérer la croissance

Croissance Sanofi CD&R Opella Santé Grand Public
PRESS RELEASE

published on 10/21/2024 at 07:30, 1 month ago

Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare as Sanofi transfers a 50% stake in Opella. Opella to become a standalone leader backed by Sanofi's strategic support and guidance

Partnership Sanofi CD&R Consumer Healthcare Opella

Accesswire

Published on 11/21/2024 at 09:00, 58 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 23 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 33 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 58 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 58 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 17 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 57 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 58 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 58 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 43 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 51 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 38 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE